Trial Profile
A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2020
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Olaparib (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 21 Sep 2020 Results of expansion part assessing safety and preliminary efficacy of adavosertib plus olaparib in patients with small cell lung cancer, presented at the 45th European Society for Medical Oncology Congress
- 08 Sep 2020 According to an AstraZeneca media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.